Xaar Share Discussion Threads

[simmsc] 20/4/2023 11:39

opinions appear to be really split on this stock. possibly as it has some growth elements in there and it also has some recovery elements to it - which make it a bit of a hybrid stock. I share napoleons view that this will go ballistic at some stage as this will very much be a needed technology for those who want to stay in the game. Once their competitors integrate (or switch back to) Xaar's print technology, the others will have to switch. Purely just from a lead time prospective alone (let alone all the other benefits that come with it - cost, quality, efficiency, ESG credentials, etc). Sit tight and hold, possibly also buy on dips at these lower prices (if you dont have a full position in it yet).

[napoleon 14th] 10/4/2023 12:12

"SCSW like them - 30p eps anticipated in 2025"

Didn't say a broker...

[aishah] 08/4/2023 23:33

Which broker is forecasting 30p? Got a link?

[napoleon 14th] 08/4/2023 22:00

This share is primed to go balistic IMO. I bought in H3'20, now up 140%.

SCSW like them - 30p eps anticipated in 2025 = P/E of 6.66666.
If 30p eps, a P/E of 20 = 600p.

"Small Caps Live Weekly" were far more stingy. I usually enjoy their "acid test"
analysis but IMO they got this one wrong.
They say "The EPS consensus of 3.02p does look achievable given the acquisitions, but this is a forward P/E of 60 and a PEG of over 2. This is still below 2021 EPS tho, so should this really be on a growth rating? Something like 10x forward earnings, or around 30p, would seem to be fair value here, given the very patchy track record."
but nowt about successful reorg. & sales prospects.
I bought on a 5 year view... Should easially double from here.

[gargoyle2] 28/3/2023 13:47

Worth a watch -- especially the commentary around Aquinox:

www.youtube.com/watch?v=wAGm7UHOZ0M

[dhurms] 28/3/2023 11:38

There is lots of growth to come. The latest product powered by our ImagineX platform, our aqueous printhead, Aquinox, was launched in November 2022. This is a significant and tremendously exciting product for the Group and enables us to compete in new sectors, such as Packaging and Textiles, with a product that we believe will deliver superior performance to any currently on the market. We have received positive feedback from customers, evidenced by high engagement and good sales of development kits.

[simmsc] 28/3/2023 08:28

One of Britain's most exciting growth stories. Very high barriers to entry in this sector and their customers are going to need this technology (as it's far superior in terms of quality, efficiency, capability, cost and speed to market). Tremendously exciting.

[ayl30] 28/3/2023 07:52

Think that underestimates the scale of the change they have made

[bookbroker] 28/3/2023 07:45

Hardly inspiring!

[ayl30] 28/3/2023 07:38

Very pleasing rns today. All dials pointing in right direction

[gargoyle2] 13/3/2023 14:22

Tipped in SCSW at the weekend -- 'I think XAR is set to become a big BUY in the latter part of the year but looking at its history, it could easily surprise positively sooner.'

[simmsc] 13/3/2023 13:31

No panic selling here!

[simmsc] 20/2/2023 13:01

Always good to see the second largest shareholder increase their stake (from 11.15% to 12.0%). Given the technological advancements (in terms of efficiency, cost and versatility) that XAAR's products now offer, the shares are cheap at current levels.


Given the obvious cost pressures that currently exist everywhere you look in the world, there will be a necessity to use XAARs cheaper and more efficient technology.


Just a matter of time until the financial figures reflect this.

[tratante] 31/1/2023 17:23

Who do you regard as possible interested parties, Simmsc?

[darrin1471] 30/1/2023 13:01

Who's selling and how many more do they have to sell?
Been watching all 2022. Bought a few around 180 and was fortunate to sell for a small profit as I wanted to put the funds elsewhere.
Looking for a new entry point.

[simmsc] 30/1/2023 12:48

Odyssean Inv. Trust increases stake in Xaar to over 11%

[simmsc] 25/1/2023 14:06

(forgot to mention the obvious ESG advantages)

[simmsc] 25/1/2023 14:05

If there are signs that this new print technology really takes off (hard to see why it wont as there are several strong advantages (efficiency, maintenance, reliability and of course financial), then there is a positive risk of someone much bigger in the world of printing world wanting (or needing to have) xaars technology in their portfolio. I think their new print technology is that good.

[napoleon 14th] 25/1/2023 13:03

Up 100%+ after 2.5 years in XAR, but greed and realism tell me to keep until £5.

[simmsc] 25/1/2023 01:46

"Progressive Equity Research" has written a 16 page detailed analysis on XAAR, focusing on the technology. They highlight how the structure and design of Xaar's printheads provide competitive advantages in overcoming the key challenges faced in several of the areas that make up the company's USD 1 billion addressable market opportunity. I've skimmed over it briefly tonight and will read in more detail over the weekend. This looks to have been written to help investors better understand where XAARS competitive advantages are (and why). Looks interesting. I am a holder, running a slight loss at the moment, and will be adding when the upward momentum picks up again on the share price

[dr biotech] 12/1/2023 16:52

Simon Thompson of the IC calls it a sell.



...cost inflation (labour and energy) is having an impact, too, prompting analysts at Progressive Equity to downgrade their 2023 pre-tax profit and earnings per share (EPS) forecasts by 44 per cent to £2.5mn and 3.2p, respectively, on revenue of £79.6mn (3 per cent downgrade)... group net cash fell by a third to £8.6mn in the second half of 2022, although analysts expect it to recover to £11.3mn by the end of 2023.


Although management is making the right strategic moves...there is no avoiding the short-term headwinds, nor the scale of the earnings downgrade. Bank the 388 per cent paper profit. Sell.

[gargoyle2] 12/1/2023 15:50

At the half year stage in September they said that the inventory build up would enable them to "deliver on customer demands throughout 2022 and further into 2023." The statement today says that the inventory acquired will "ensure availability of product during the factory reorganisation in Q1 2023 and the remainder of the year."

So clearly they have been looking further ahead until the end of 2023, hence the further cash drain. Nothing as far as inventory is concerned to suggest missed sales targets imo, although they acknowledge that China has been challenging. With luck, that will change over Q1.

[mr macgregor] 12/1/2023 15:28

I'm surprised they burnt £4.1m in H2 as they'd already built significant inventory in H1. Suggests to me they're not meeting sales targets. With short term headwinds I think cash burn will continue and without significant increase in sales they may look to a raise mid-year to tide them over. In short they claim the balance sheet is strong but I don't agree.

[ny boy] 12/1/2023 12:37

No doubt short term problems, so a buying opportunity coming up imo

Will watch over the next few weeks

[dr biotech] 12/1/2023 10:20

From progressive. Really I guess we will see how successful the new print head will be towards the back of this year.


Strong FY22 but China and costs impact FY23
Xaar’s update for the year ended 31 December 2022, issued today, states that revenue is expected to be c.£74m and adjusted PBT ‘on track’. This revenue figure is slightly ahead of our estimate but more importantly 24% ahead of the prior year, with much of this growth having been organic. We adjust our expectations for FY23 to reflect an element of ongoing caution on China, as well as cost increases across the business. However, with its aqueous printhead, Aquinox, successfully launched and the factory reorganisation expected to be complete by March, Xaar remains on the front foot from strategic, operational and financial perspectives. Nothing has fundamentally changed within the business – our new outlook for FY23 is more prudent, but hopefully allows for strong growth in FY24 estimates, which we expect to introduce with results in March.